An evolved AAV variant enables efficient genetic engineering of murine T cells
Cell · 2023
DOI: 10.1016/j.cell.2022.12.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2023. Verfasst von William A Nyberg und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone-UCSF Institute of Genomic Immunology, San Fr…. Hauptthemen laut MEDLINE: Dependovirus, Genetic Engineering, T-Lymphocytes. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Precise targeting of large transgenes to T cells using homology-directed repair has been transformative for adoptive cell therapies and T cell biology. Delivery of DNA templates via adeno-associated virus (AAV) has greatly improved knockin efficiencies, but the tropism of current AAV serotypes restricts their use to human T cells employed in immunodeficient mouse models. To enable targeted knockins in murine T cells, we evolved Ark313, a synthetic AAV that exhibits high transduction efficiency in murine T cells. We performed a genome-wide knockout screen and identified QA2 as an essential factor for Ark313 infection. We demonstrate that Ark313 can be used for nucleofection-free DNA delivery, CRISPR-Cas9-mediated knockouts, and targeted integration of large transgenes. Ark313 enables preclinical modeling of Trac-targeted CAR-T and transgenic TCR-T cells in immunocompetent models. Efficient gene targeting in murine T cells holds great potential for improved cell therapies and opens avenues in experimental T cell immunology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA.
- Department of Molecular Genetics & Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.
- Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA; Biomedical Sciences Graduate Program, Universi…
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94131, USA.
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA; Université de Paris Cité, INSERM UMR976, Hôpit…
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NHLBI NIH HHS
- Howard Hughes Medical Institute
- NHGRI NIH HHS
Zitieren
APA
Nyberg, W. A., Ark, J., To, A., Clouden, S., Reeder, G., Muldoon, J. J., Chung, J. Y., Xie, W. H., Allain, V., Steinhart, Z., Chang, C., Talbot, A., Kim, S., Rosales, A., Havlik, L. P., Pimentel, H., Asokan, A., & Eyquem, J. (2023). An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell. https://doi.org/10.1016/j.cell.2022.12.022
Vancouver
Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, et al. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell. 2023. doi:10.1016/j.cell.2022.12.022
BibTeX
@article{Nyberg2023,
author = {Nyberg, William A and Ark, Jonathan and To, Angela and Clouden, Sylvanie and Reeder, Gabriella and Muldoon, Joseph J and Chung, Jing-Yi and Xie, William H and Allain, Vincent and Steinhart, Zachary and Chang, Christopher and Talbot, Alexis and Kim, Sandy and Rosales, Alan and Havlik, L Patrick and Pimentel, Harold and Asokan, Aravind and Eyquem, Justin},
title = {An evolved AAV variant enables efficient genetic engineering of murine T cells},
journal = {Cell},
year = {2023},
doi = {10.1016/j.cell.2022.12.022}
}
EUVIMED